

1 **A systematic review of handgrip strength measurement in**
2 **clinical and epidemiological studies of kidney disease:**
3 **towards a standardized approach**

4

Thomas J. Wilkinson, PhD ^{1,2}	tjw26@le.ac.uk	0000-0002-7855-7752
Iwona Gabrys, BKin ³	igabrys12@gmail.com	0000-0001-7247-3278
Courtney J. Lightfoot, PhD ^{1,2}	courtney.lightfoot@le.ac.uk	0000-0002-5855-4159
Kelly Lambert, PhD ⁴	klambert@uow.edu.au	0000-0001-5935-7328
Luke A. Baker, PhD ¹	lab69@le.ac.uk	0000-0003-2111-3832
Roseanne E Billany, MPhil ⁵	r.billany@le.ac.uk	0000-0001-9610-4717
Archontissa Kanavaki, PhD ¹	mak57@leicester.ac.uk	0000-0003-2630-1437
Jared Palmer, BSc. ¹	jp510@leicester.ac.uk	0000-0001-9667-8016
Katherine A. Robinson, BSc ⁵	kr222@leicester.ac.uk	0000-0001-9209-454X
Daniel Nixon, MSc. ¹	daniel.nixon@le.ac.uk	0000-0002-7274-7758
Emma L. Watson, PhD ⁵	emma.watson@le.ac.uk	0000-0002-3869-8972
Alice C. Smith, PhD ^{1,2}	alice.smith@le.ac.uk	0000-0002-9234-9060

5

6 ¹Leicester Kidney Lifestyle Team, Department of Health Sciences, University of Leicester,
7 Leicester, UK

8 ²Leicester Biomedical Research Centre, Leicester, UK

9 ³Alberta Kidney Care North, University of Alberta Hospital, Edmonton, AB, Canada

10 ⁴School of Medicine, Faculty of Science, Medicine and Health and The Illawarra Health and
11 Medical Research Institute, University of Wollongong, Wollongong NSW, Australia

12 ⁵Department of Cardiovascular Sciences, University of Leicester, Leicester, LE17RH

13

14 **Corresponding author:** Dr Thomas J. Wilkinson, t.j.wilkinson@leicester.ac.uk. Leicester
15 Kidney Lifestyle Team, Department of Health Sciences, University of Leicester, Leicester, UK,
16 LE17RH. ORCID ID: 0000-0002-7855-7752

17

18 **Running head:** Handgrip strength assessment in CKD

19

20 Total number of words (manuscript): 4500

21 Total number of words (abstract): 149

22 Number of figures: 2

23 Number of tables: 2

24

25 **Acknowledgments**

26 This report is independent research supported by the National Institute for Health Research
27 Leicester Biomedical Research Centre. The views expressed are those of the author(s) and not
28 necessarily those of the Stoneygate Trust, NHS, National Institute for Health Research
29 Leicester BRC or the Department of Health.

30

31 **Declaration of conflicting interests**

32 The author(s) declared no potential conflicts of interest with respect to the research,
33 authorship, and/or publication of this article.

34

35 **Author contributions**

36 Conceptualization: TJW; Abstract review: TJW; Extraction of full text data: All authors;
37 Analysis and data synthesis: TJW; Writing - original draft preparation: TJW; Funding
38 acquisition: ACS. All authors have full access to all the data in the study and takes
39 responsibility for the integrity of the data and the accuracy of the data analysis. All authors
40 gave final approval.

41

42 **Funding**

43 This work was part-funded by the Stoneygate Trust and supported by the National Institute
44 for Health Research Leicester Biomedical Research Centre (BRC).

45

46 **Supplementary material**

47 Supplementary material 1. Full search strategies

48 Supplementary material 2. Summary of handgrip strength measurement protocols

49 Supplementary material 3. Link to file containing all extracted data

50

51

52 In chronic kidney disease (CKD), handgrip strength (HGS) is recommended as a surrogate
53 measure of protein-energy status and functional status. However, it is not routinely used due
54 to inconsistencies such as the optimal timing of the HGS measurement and unclear guidance
55 regarding technique. We aimed to determine the extent of variation in the protocols and
56 methods of HGS assessment. We aimed to identify clinical and epidemiological studies
57 conducted in CKD that reported on the use of HGS as an outcome. A systematic literature
58 search identified n=129 studies with a total participant population of n=35,192. We identified
59 large variations in all aspects of the methodology including body and arm position,
60 repetitions, rest time, timing, familiarization, and how scores were calculated. The
61 heterogeneous methodologies employed reinforce the need to standardize HGS
62 measurement. After reviewing previously employed methodology in the literature, we
63 propose a comprehensive HGS assessment protocol for use in CKD.

64

65 **Key words**

66

67 Handgrip strength; chronic kidney disease, systematic review

68

69 **Introduction**

70

71 Chronic kidney disease (CKD) is characterized by reductions in physical function and strength
72 that has a detrimental effect on quality of life (QoL) and is associated with morbidity and
73 mortality [1]. Handgrip strength (HGS) has emerged as a simple and reliable method to
74 evaluate muscle function [2] and in studies of the general population [3-5], older adults [6],
75 and clinical conditions [2, 7, 8], low HGS has emerged as an independent predictor for poor
76 cognition, mobility, and mortality. Handgrip strength forms a prominent role in the detection
77 of muscle weakness as part of the frailty and sarcopenia phenotype [9] and the possibility of
78 modifying HGS through interventions, such as exercise, make it a popular amenable outcome
79 measure [10].

80

81 Given its low cost and ease of assessment, HGS is widely used in clinical and epidemiological
82 studies involving patients with CKD as a method of nutritional and functional assessment [11,
83 12]. In patients with non-dialysis dependent CKD, HGS is an independent predictor of
84 mortality [13-16] and dialysis initiation [15, 16], whilst in dialysis patients, HGS is associated
85 with nutritional status [12, 17]. A recent meta-analysis found the summary risk ratio of all-
86 cause mortality associated with a 1-kg unit increase in HGS was 0.95 (0.93-0.97) [18].
87 Nonetheless, some studies suggest HGS is relatively preserved compared with lower limb
88 strength [19] and has no association with body composition or nutritional status in peritoneal
89 dialysis (PD) patients [20].

90

91 The 2020 'KDOQI Clinical Practice Guideline for Nutrition in CKD' recommend that in adults
92 with CKD 1-5D, HGS is used as a surrogate measure of protein-energy status and functional

93 status [21, 22]. The cited rationale is based on the relationship of HGS with nutritional status
94 (e.g., malnutrition inflammation score [23, 24]) and inflammatory markers [25]).
95 Nevertheless, whilst HGS is widely used in clinical studies, it is not routinely implemented in
96 practice. Reasons for this lack of application are partly due to inconsistencies in guidance such
97 as the optimal timing of the measurement (e.g., pre- or post- hemodialysis (HD) session, non-
98 dialysis day) and equivocal information regarding technique [11, 21].

99

100 The lack of standardization of this routine and recommended measure is somewhat worrying
101 as even small inconsistency in technique and protocol may result in invalid measurement and
102 risk of error rendering its value inadequate. In order to propose a standardized protocol and
103 measurement procedure for the assessment of HGS in CKD we conducted a systematic review
104 to evaluate the current literature on HGS methodology. We aimed to determine the degree
105 of protocol variation in HGS assessment, before using this information to propose a
106 standardized method for future measurement in CKD.

107

108 **Methods and materials**

109

110 A systematic literature search was undertaken per the PRISMA statement [26]. The protocol
111 was prospectively registered on PROSPERO (CRD42020206097).

112

113 **Eligibility criteria**

114 We aimed to identify clinical and epidemiological studies conducted in CKD that reported the
115 use of HGS as an outcome measure. All types of studies were included, including
116 interventional trials of any component. Studies using handgrip-based training to elicit a
117 response (e.g., changes in blood pressure) were excluded. Review studies, abstracts, animal
118 trials, and non-English articles were excluded. To aid data synthesis and to focus on
119 contemporary methodology, we limited studies to those conducted in the last five years (i.e.,
120 1st January 2016 to the date of search). Adult participants with a diagnosis of CKD were
121 included (i.e., CKD1-5 including those on dialysis and kidney transplant recipients (KTRs)).

122

123 **Types of outcome measures**

124 The primary outcome was HGS and its use in any form. We were specifically interested in the
125 variation in HGS protocol and methodology. No secondary outcomes were assessed.

126

127 **Information sources**

128 The following databases were searched: National Centre for Biotechnology Information
129 (NCBI) PubMed [which includes the Medical Literature Analysis and Retrieval System Online
130 (MEDLINE)], Excerpta Medica database (EMBASE), and the Cochrane Central Register of
131 Controlled Trials (CENTRAL).

132

133 **Search strategy**

134 The following MESH search terms were used to search all databases: 'Kidney'; 'Kidney
135 Diseases'; 'Kidney Transplantation'; 'Dialysis'; 'Peritoneal Dialysis'; 'Renal Dialysis'. In
136 addition, non-MeSH terms 'Handgrip' and 'Handgrip strength', along with MeSH Descriptors
137 'Pinch strength' and 'Muscle strength dynamometer' were used. Full search strategies for
138 each database can be found in **supplementary material 1**. A flow of information through the
139 different phases of the search can be found in the PRISMA diagram, **Figure 1**.

140

141 **Data collection process and data items**

142 Following a preliminary pilot search in NCBI PubMed, a bespoke data extraction form was
143 created. Prior to data extraction, this form was piloted by all the researchers on three papers
144 selected at random. Following this pilot, the extraction form was amended. Each article was
145 reviewed by an independent member of the team. If means were presented for different
146 groups, pooled values were calculated [27]. Due to the nature of the review, risk of bias was
147 not assessed.

148

149 The following information was extracted: 1) study; and 2) patient characteristics. Based on
150 Roberts et al. [28] and Shiratori et al. [29], the following were extracted: 1) equipment type;
151 2) measurement protocol (e.g., hand size and nail length, hand dominance, jewellery removal,
152 acquisition time); 3) HGS data; 4) body position (i.e., wrist/forearm, elbow, shoulder,
153 posture); 5) effort and encouragement; 6) interval (rest) between measurements; 7) time of
154 day; 8) training of assessors; 9) clinimetric properties; and 10) familiarization/practice tests.

155 We also extracted, where appropriate, information pertaining to CKD: 1) the timing of the

156 measurement (e.g., pre- or post-HD session, non-dialysis day); 2) any confounding effects of
157 other conditions; 3) type of access (e.g., central venous catheter or a fistula/graft); 4) any
158 information regarding fluid gain or ultrafiltration rate; and 5) any contraindications noted
159 prior to testing.

160

161 **Results**

162

163 A PRISMA diagram can be found in **Figure 1** whilst a summary of included studies can be found
164 in **supplementary material 2**. A link to the full data file can be found in **supplementary**
165 **material 3**.

166

167 **Summary of study characteristics**

168 In summary, n=129 studies were eligible for inclusion with a total population of n=35,192.
169 Study samples ranged from n=14 to 18,765. The median study sample size was n=90. Thirty
170 (23%) studies assessed only non-dialysis dependent CKD1-5, n=80 (62%) in dialysis only [of
171 which, n=52 (41%) were conducted in HD], and n=11 (9%) in KTRs. Studies were conducted in
172 28 countries with Brazil (n=20 studies) and the UK (n=10) undertaking the most. Ninety-three
173 studies (73%) had observational designs and n=24 (19%) were experimental.

174

175 **Summary of participant characteristics**

176 The mean age was 59.5 (range: 36.2 to 77.3) years. Ethnicity was poorly reported with n=105
177 studies providing no data. In studies that did, 54% of patients were White. Males made up an
178 average of 62% of each study population. Where eGFR was reported the average was 38.5
179 (range: 16.9 to 68.5) ml.min.⁻¹.73². Mean body mass index as 25.7 (range: 20.3 to 29.4) kg/m².
180 Mean albumin was 39.0 (range: 26.3 to 63.0) mg/g and hemoglobin was 112.1 (range: 61.5 to
181 132.0) g/L. The reported prevalence of hypertension was 65.3%, 35.4% had diabetes, and
182 27.8% had cardiovascular disease (CVD).

183

184 **Handgrip strength data**

185 The majority of studies (n=75, 59%) did not report HGS data. When stated, the mean HGS was
186 26.4 (range: 9.5 to 55.0) kg. Most studies (n=88, 69%) measured HGS in kilograms (kg). Ten
187 studies used kilogram-force (kgf). One study used kg/m² [30]. Two studies reported pounds
188 (lbs) [31, 32] whilst another reported Newtons (N) [33]. Twenty-five studies did not report
189 units.

190

191 *Cut-off criteria used to define low muscle strength*

192 In studies using HGS as a measure of sarcopenia or to define low strength, n=6 studies used
193 the Asian Working Group for Sarcopenia (AWGS) cut-offs, whilst n=20 used variations of the
194 European Working Group on Sarcopenia in Older People (EWGSOP) (n=15 used the older
195 EWGSOP cut-off, n=5 used the revised EWGSOP cut-off).

196

197 **Handgrip strength protocols**

198

199 *Equipment*

200 The most frequently used dynamometer was Jamar[®] (n=55, 43%). The Jamar[®] Plus was
201 specified in n=8 studies. The model of Jamar[®] was not specified in n=43 of the studies. The
202 second most frequently used dynamometer make was Takei[®] (n=22, 17%). The most
203 commonly reported model was the Takei[®] GRIP-D (n=8). Other makes of dynamometer
204 included Yamar[®] (n=7), Saehan[®] (n=6), and CAMRY[®] (n=5). The type of dynamometer was
205 poorly reported with n=11 studies simply specifying a digital model was used with n=20
206 stating the instrument was hydraulic.

207

208 *Contraindication prior to testing*

209 In one study, patients were excluded if they could not complete the test [34], whilst in another
210 patients were excluded if they showed signs of hand ischemia [31].

211

212 *Body position*

213 Thirty (23%) studies specified that HGS was performed while sitting, whilst n=14 were
214 conducted standing. Two were conducted whilst supine [35, 36] and one [37] stated patients
215 could either sit or stand. Eighty-two (64%) studies did not report position. A 90° elbow flexion
216 was specified in n=24 studies (n=17 of which were sitting, n=7 did not report position). Two
217 studies stated the elbow was fully extended (180°), one standing [38] and the other sitting
218 [39]. The remaining n=103 studies did not report position. Fourteen studies stated the
219 forearm was placed in a neutral position. Specific wrist position was specified in two studies:
220 one study [40] reported the wrist was between 0-15° ulnar deviation, and 0-30° dorsiflexion
221 in another [41]. The shoulder position was stated in n=23 (18%) studies. Most of these studies
222 (n=19) reported that the shoulders were adducted, n=3 stated the arms were abducted [30,
223 42, 43], whilst n=1 stated the shoulders were in a neutral position [44].

224

225 *Hand selection*

226 Forty-one (32%) studies tested both hands, whilst n=59 (46%) tested HGS in one hand only.
227 The remaining studies did not report which hand was used. The dominant hand was tested in
228 n=34 (27%) studies. Dominance was not stated in the other studies that used only one hand.
229 In those with a fistula, n=36 studies reported that HGS was assessed in the non-fistula arm.
230 One study assessed HGS in both hands of HD patients [45].

231

232 *Instructions effort or encouragement*

233 Twenty studies (16%) explicitly stated they gave participants verbal instruction to ‘exert
234 maximal force’ or a variation of such. The majority of studies (n=103) did not report if
235 encouragement was given.

236

237 *Contraction time*

238 Only n=4 studies [44, 46-48] reported an explicit contraction time where patients were asked
239 to exert maximal effort for 5 seconds.

240

241 *Warm-up and familiarization testing*

242 A warm-up consisting of submaximal handgrip contractions was used by one study [44].
243 Whilst in another, patients were asked to shake their hand three times [49]. In two studies
244 [50, 51], the first trial was discarded as a ‘warm-up’. Eleven studies incorporated a form of
245 familiarization with the equipment which involved patients being instructed and shown how
246 to use the equipment. The remaining n=118 (92%) did not report the use of familiarization.

247

248 *Assessment repetitions*

249 Most studies (n=86, 67%) performed three assessments in each hand. Three studies
250 performed one assessment, n=11 performed two, n=2 performed four assessments, and n=1
251 performed six assessments. The remaining n=26 (20%) studies did not report the repetitions
252 used. Only one trial specified that hands were tested alternatively (i.e., right, left, etc.) [52].

253

254 *Rest time*

255 Thirty (30%) studies reported rest time: 10-20 seconds was used by n=2 studies; 15 seconds
256 by n=2 studies; 20 seconds by n=1 study; 30-seconds by n=8 studies; 90-seconds by n=1 study;

257 3-minutes by n=1 study; and 5-minutes by n=5 studies. 'At least' 10 and 30 seconds was used
258 by n=3 studies, whilst n=2 studies reported giving 'at least' 5-minutes rest. The most
259 frequently reported rest time was 1-minute, used by n=14 (11%) studies. Rest time was not
260 reported in the remaining n=90 studies (70%).

261

262 *Calculating a score*

263 The most frequent method to generate a score was to use the maximal score (n=67, 52%),
264 followed by the average of all trials performed in that hand (n=29, 23%). Four studies used
265 the average of the maximal score from each hand, whilst n=2 reported the median value. The
266 other n=27 (21%) did not report how they calculated HGS score. One study combined the HGS
267 of both hands to report a combined kg value [53].

268

269 *Testing time*

270 Forty of the studies involving patients undergoing dialysis reported information on the time
271 of day assessments took place (relative to dialysis schedule). Six studies (5%) assessed HGS
272 *after* dialysis. Specific details were provided in several studies, such as that assessment should
273 take place *at least 18-24 hours* following last session [38], another stating testing should take
274 place *at least 24-hours after* [54], and another *at least 30 minutes after* [55]. Marini et al. [56]
275 reported that assessment should take place *after the middle dialysis session* of the week to
276 avoid alteration in hydration status.

277

278 Eighteen studies reported assessments *before dialysis*, with Bogataj et al. [57] stating this
279 should be *at least 30-minutes before*. Five studies reported performing HGS *during* dialysis,
280 particularly during the mid-week session [42, 58] and within the first hour of dialysis [37, 59].

281 The remaining n=6 studies stated performing HGS on a non-dialysis day, with n=3 of these
282 performing assessments in the afternoon [60-62]. In PD, testing was done during PD clinic
283 visits, although type of clinic was not reported [59].

284

285 *Training of assessor*

286 No specific details of how the assessor was trained were mentioned in any study.

287

288 *Adverse outcomes*

289 No adverse events were reported specifically related to the HGS assessment.

290

291 **Discussion**

292

293 Despite HGS being recommended in CKD [21], little attention has been paid to the significance
294 of standardization of the test protocol itself. Such standardization is important to improve the
295 accuracy and consistency of the test since differences can affect the reproducibility and the
296 comparison across studies. This review examined 129 studies with over 35,000 participants
297 across the CKD spectrum. We identified large variations in all aspects of the HGS methodology
298 reported. Here we discuss these findings in context before making recommendations towards
299 a standardized approach in **Table 1** with a checklist on reporting HGS protocols in **Table 2**.

300

301 Variations of the Jamar[®] dynamometer were the most widely used instruments. In the 1990's,
302 the American Society of Hand Therapists (ASHT) recommended the Jamar[®] dynamometer
303 leading to its widespread use [63]. Jamar[®] is now widely accepted as the gold standard by
304 which other dynamometers are evaluated [28] and research has shown excellent inter-
305 instrument reliability exists between Jamar[®] and other commonly used dynamometers (e.g.,
306 Baseline, MicroFET); this suggests they could be used interchangeably [64]. The other most
307 frequently reported dynamometer was from Takei[®], specifically the D-Grip. Study in healthy
308 volunteers from Brazil showed significant differences between the Jamar[®] and Takei[®]
309 dynamometers which could be due to the influence of the handle shapes; Jamar[®] has a
310 superior anatomical shape [65]. However, both dynamometers have been shown comparable
311 in patients with cystic fibrosis [66] and healthy young adults [65]. To our knowledge, no study
312 has compared devices in a CKD population. It is important to note that both the Jamar[®] and
313 Takei[®] devices may not be the most appropriate for those with very poor HGS as both
314 dynamometers are unable to detect forces <5kg [67, 68]. In a sample of n=209 adult HD

315 patients, 5% of patients scored <5kg. Regardless of dynamometer make and model,
316 appropriate calibration as per the manufacturer's instructions should be performed and
317 follow-up testing should be performed using the same instrument.

318

319 The recent KDOQI guidelines [21, 22] highlighted future research should determine the
320 standardization of the arm position, evaluation period, and choice of arm side. We noted
321 considerable variation in the body position during the assessment. Firstly, studies reported a
322 mixture of sitting and standing positions. It has previously been shown that no significant
323 difference in HGS occurs when either sitting or standing [69, 70], although results are not
324 *entirely* equivocal [71]. Nonetheless, given that any differences in posture are likely to have
325 minimal effect on the readings, like Horner et al. [37] from our review, we suggest patients
326 should be either sat or stood depending on their capacity. This may be particular pertinent to
327 patients with poor balance or mobility.

328

329 Few studies reported the handle settings for the instrument. Jiang et al. [72] stated that in
330 patients with CKD4-5, the "handle was adjusted to ensure fingers were properly rested on the
331 handle." For the Jamar® dynamometer, there are five handle positions available, however the
332 second position is the most reliable [73] and recommended by the ASHT [63, 74, 75].
333 However, the Southampton protocol is broader, suggesting the handle should be adjusted so
334 the thumb is around one side of the handle and the fingers are around the other [28]. It should
335 be specified that HGS using the Jamar® second position is reduced in those with fingernails
336 extending >1cm beyond the fingertip, and for position one, HGS is reduced with fingernails
337 projecting 0.5cm [76].

338

339 Most studies in the review reported an elbow flexion of 90°. Higher grip strength has been
340 reported with the elbow in 90° flexion rather than fully extended [77, 78], although findings
341 are equivocal [79]. Our review showed the majority of studies reported an adducted shoulder
342 position (i.e., arms down by the side, 0°). Su et al. found the highest mean HGS score was
343 recorded when the shoulder was positioned at 180° of flexion (i.e., overhead) with the elbow
344 in full extension, whereas (the position commonly reported this review) 90° elbow flexion
345 with a shoulder flexion of 0° produced the lowest HGS score [80]. Conversely, other studies
346 have reported no differences when shoulder joints varied between 90° and 180° [78] or 0 and
347 180° shoulder flexion [81]. Given the complex nature of shoulder movement and risk of injury
348 in a population characterized by deconditioning and poor mobility [82], we suggest HGS
349 should safely be performed with the elbow in 90° flexion and the shoulder adducted (0°).

350

351 Regarding the wrist position, most studies reported that the forearm was placed in a neutral
352 position. Although Hasheminejad et al. [40] stated the wrist was between 0-15° ulnar
353 deviation and Taşoğlu et al. [41] reported of 0-30° dorsiflexion. Previous work has suggested
354 that a minimum of 25° of wrist extension was required for optimum grip strength [83].
355 Handgrip strength measured with the wrist in a neutral position was significantly higher than
356 that in the wrist ulnar deviation [78]. In another study, the HGS was higher when the wrist
357 was positioned in neutral [81]. The ASHT recommends the forearm in neutral and wrist
358 between 0 and 30° of dorsiflexion [63].

359

360 It is well known there are differences of around 10% in HGS between the dominant and non-
361 dominant hands [29]. In those on dialysis with a fistula, most studies reported that HGS was
362 assessed in the *non-fistula* arm. A review by Leal et al. [84] suggested that measuring HGS on

363 the fistula arm could result in problems such as a risk of bleeding if the arm is overexerted.
364 Nonetheless, studies [45, 67, 85, 86] have measured HGS on the fistula arm, although this
365 generally occurs before connection and just after disconnection (after bleeding stopped) to
366 limit the impact on the fistula itself. Studies have shown HGS is generally lower in the access
367 arm. El-Katab et al. [67] found a significant difference of 2.4kg (15%) between the fistula and
368 non-fistula arm. Similarly, Omichi et al. [45] reported HGS was lower in the fistula access arm
369 compared to the non-access arm (a difference of 3.9kg (21%) in right arm, and 1.1kg (7%) in
370 left arm) in HD patients, i.e., HGS was greater in the left arm for those dialyzing with right arm
371 vascular access and vice versa. Whilst this suggests that the presence of a fistula may impact
372 HGS compared to the contralateral arm, it is important to note that such data may be
373 confounded by the surgical practice to form the fistula in the *non-dominant* arm. As such it
374 seems desirable to make measurements *in the non-fistula arm* to improve reliability and
375 safety.

376

377 Only 16% of studies explicitly stated they gave participants verbal instruction to ‘exert
378 maximal force’ or a variation of such. Different instructions and verbal encouragement, even
379 the volume of said instruction [78], can affect performance [70, 75, 87]. The contraction time
380 per HGS trial was poorly described with only four studies reporting an explicit contraction
381 time of 5 seconds. The ASHT protocol states the acquisition time should be at least 3 seconds.
382 There is limited research into the differences in sustained isometric contractions of the hand.
383 Kamimura and Ikuta [88] showed in healthy students that there were no differences in peak
384 strength values between a 6-second and 10-second test. Moreover, peak HGS occurred after
385 1 second in both tests. As such, an acquisition time of at least 3 seconds is likely to be
386 sufficient.

387

388 One of the largest sources of variation between studies was the method used to generate a
389 HGS score. The majority of studies (67%) performed three assessments in each hand as per
390 other studies in the literature [28, 75]. Most studies used the highest value for analysis,
391 however other ways of recording HGS included the mean, median, or the sum of values
392 obtained. It has been suggested the *mean of three attempts* has the highest test-retest
393 reliability and consistency [29], and that the mean of three trials is more accurate than one
394 trial or the highest score of three trials [77]. Contrariwise, it has been stated that muscle
395 fatigability might increase with each subsequent attempt and that one trial is sufficient [89].
396 A study in 66 participants with forearm injuries observed that the values generated for three
397 methods (one trial, mean, and highest) produced comparable results [90]. Given the high
398 prevalence of fatigue and poor muscle function in CKD, we suggest that taking the *maximal*
399 *score from three attempts* should be used, as fatigability will not influence the mean.
400 However, one trial should be sufficient if short on time. We observed variation in the units
401 presented. Most studies reported HGS in kg, a SI unit, however other values (e.g., kgf) were
402 used. Whilst units may be converted to kg, the use of non-standard units make comparisons
403 difficult.

404

405 The rest time reported between each trial varied substantially, between 10 seconds and 5
406 minutes. The most frequently reported rest time was 1 minute. The resting interval between
407 trials can influence strength performance because this variable is directly related to muscle
408 fatigue. Shiratori et al. [29] recommended a rest period of *at least 1 minute* to counteract the
409 effects of fatigue, whilst the ASHT protocol states the rest time should be *at least 15 seconds*.
410 To minimize the total time for the test, hands can be tested alternately (i.e., right, left, etc.)

411 such as performed in D'Alessandro et al. [52] and stated in the Southampton protocol [28].
412 Only a small number of studies (n=4) specified any form of warm-up, whilst only n=11 studies
413 incorporated some form of familiarization. In two studies [50, 51], the first trial was discarded
414 as a 'warm-up'. There is limited research exploring the effect of including practice or
415 familiarization testing, although as described above, given the reliability of performing just
416 one trial [90], it appears that they may not be required.

417

418 The KDOQI workgroup recommended further research on the timing of the HGS
419 measurement (e.g., pre- or post-HD session, non-dialysis day) [21, 22]. We found that n=18
420 studies reported assessments *before* dialysis, with Bogataj et al. [57] stating this should be at
421 least 30-minutes before. A recent study in 101 HD patients showed a significant decline (~4kg,
422 41%) in HGS *after* dialysis compared to values *before* [85]. However, Leal et al. [84] showed
423 no difference pre-post dialysis session. Hall et al. [91] suggested performing HGS testing
424 *before* a HD session to avoid limiting participation due to post-dialysis complications (e.g.,
425 cramps or hypotension). However, considerations pre-dialysis includes fluid overload and
426 hypertension and should be determined before undergoing HGS testing. Delaney et al. [85]
427 assessed HGS *before* HD connection and just *after* disconnection (after bleeding stopped).
428 Five studies reported performing HGS *during* dialysis, particularly during the mid-week
429 session [42, 58] and *within* the first hour [37, 59]. There is limited evidence on how HGS results
430 could be influenced by the dialysis session itself (and events that can occur such as
431 hypotension) [85]. The remaining studies stated assessment should take place on a *non-*
432 *dialysis* day. Hall et al. [91] reported that in 37 community-dwelling older adults receiving HD
433 good agreement between 'short physical performance battery' scores on dialysis days and
434 non-dialysis days, although it remains unknown if agreement upholds for HGS. As such,

435 assessment of HGS *before* a dialysis session, or on a *non-dialysis day* if possible, is preferential.
436 As with other physical function assessments [92, 93], to limit the variability in physiologic
437 status and dialysis fatigue, HGS should be assessed before the participant's *mid-week dialysis*
438 *session*.

439

440 No adverse events were reported specifically related to the HGS assessment and only one
441 study reported a contraindication relevant to the hand. Kmentova et al. stated that patients
442 should be excluded if they showed clinical signs of hand ischemia [31]. There are few reported
443 contraindications to HGS in the literature, although testing is generally contraindicated before
444 full healing following a fracture, ligament repair, tendon laceration, or tendon transfer of the
445 forearm, wrist, or hand [94]. Isometric exercise, including HGS testing [95], is associated with
446 acute hemodynamic changes consisting of increases in systolic, diastolic, and arterial
447 pressure, as well as increased heart rate and cardiac output [96]. Caution should be applied
448 to those with uncontrolled hypertension or CVD.

449

450 **Strengths and limitations**

451 To our knowledge, there is no other systematic review of literature that comprises a detailed
452 description of the methods of HGS in observational and experimental studies in CKD. We were
453 able to include a large number of studies (n=129) encompassing over 35,000 participants.
454 Given the large number of studies assessing HGS, we limited our review to English articles
455 conducted in the last 5 years to provide an overview of contemporary research. The aim of
456 the present review was to gather information regarding HGS methods, hence, we did not
457 evaluate the quality of the studies included.

458

459 **Gaps in the literature**

460 Along with determining cut-off values correlated with measures of nutritional status,
461 assessing the reliability and validity, and exploring the association with other markers of
462 function (as recommended by the KDOQI workgroup [21, 22]), other areas for research
463 include: directly comparing devices; investigating how HGS could be influenced by the dialysis
464 session; and explore differences in HGS between dialysis and non-dialysis days. One
465 component that was not extracted in the current review was the use of feedback - a variable
466 not well documented [29]. Jung et al. [97] found providing real-time visual feedback increased
467 HGS by 7-10%. Therefore, further research is needed to determine the role of visual and
468 verbal feedback in CKD.

469

470 **Conclusion and practical applications**

471 The diverse methodologies employed in CKD research reinforce the need to standardize HGS
472 measurement. After reviewing previously employed methodology in the literature, we have
473 proposed a comprehensive HGS assessment protocol for use in CKD (**Table 1**). Researchers
474 should always include a detailed description of the methodology employed; a proposed
475 checklist can be found in **Table 2**. Any differences in protocols can influence the HGS results
476 and, consequently, affect the comparability between the studies. A collective approach is not
477 only important for research purposes but also for clinical practice.

478

479 **References**

480

481 1. MacKinnon HJ, Wilkinson TJ, Clarke AL, Gould DW, O'Sullivan TF, Xenophontos S, et al.
482 The association of physical function and physical activity with all-cause mortality and adverse
483 clinical outcomes in nondialysis chronic kidney disease: a systematic review. *Ther Adv Chronic*
484 *Dis.* 2018; 9(11):209-226.

485 2. McGrath R. Are we maximizing the utility of handgrip strength assessments for
486 evaluating muscle function? *Aging Clin Exp Res.* 2020. Epub ahead of print.

487 3. Celis-Morales CA, Welsh P, Lyall DM, Steell L, Petermann F, Anderson J, et al.
488 Associations of grip strength with cardiovascular, respiratory, and cancer outcomes and all
489 cause mortality: prospective cohort study of half a million UK Biobank participants. *BMJ.* 2018;
490 361:k1651.

491 4. Yates T, Zaccardi F, Dhalwani NN, Davies MJ, Bakrania K, Celis-Morales CA, et al.
492 Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer
493 mortality: a UK Biobank observational study. *Eur Heart J.* 2017; 38(43):3232-3240.

494 5. Zaccardi F, Davies MJ, Khunti K, Yates T. Comparative Relevance of Physical Fitness
495 and Adiposity on Life Expectancy: A UK Biobank Observational Study. *Mayo Clin Proc.* 2019;
496 94(6):985-994.

497 6. Rijk JM, Roos PR, Deckx L, van den Akker M, Buntinx F. Prognostic value of handgrip
498 strength in people aged 60 years and older: A systematic review and meta-analysis. *Geriatr*
499 *Gerontol Int.* 2016; 16(1):5-20.

- 500 7. Hamasaki H, Kawashima Y, Katsuyama H, Sako A, Goto A, Yanai H. Association of
501 handgrip strength with hospitalization, cardiovascular events, and mortality in Japanese
502 patients with type 2 diabetes. *Sci Rep.* 2017; 7(1):7041.
- 503 8. Kilgour RD, Vigano A, Trutschnigg B, Lucar E, Borod M, Morais JA. Handgrip strength
504 predicts survival and is associated with markers of clinical and functional outcomes in
505 advanced cancer patients. *Support Care Cancer.* 2013; 21(12):3261-70.
- 506 9. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T; Writing Group for
507 the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended
508 Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis.
509 *Age Ageing.* 2019; 48(4):601.
- 510 10. Labott BK, Bucht H, Morat M, Morat T, Donath L. Effects of Exercise Training on
511 Handgrip Strength in Older Adults: A Meta-Analytical Review. *Gerontology.* 2019; 65(6):686-
512 698.
- 513 11. Viramontes-Hörner D, Taal MW. Nutritional status assessment: a neglected biomarker
514 in persons with end-stage kidney disease. *Curr Opin Nephrol Hypertens.* 2020; 29(6):547-554.
- 515 12. Leal VO, Mafra D, Fouque D, Anjos LA. Use of handgrip strength in the assessment of
516 the muscle function of chronic kidney disease patients on dialysis: a systematic review.
517 *Nephrol Dial Transplant.* 2011; 26(4):1354-60.
- 518 13. Pereira RA, Cordeiro AC, Avesani CM, Carrero JJ, Lindholm B, Amparo FC, et al.
519 Sarcopenia in chronic kidney disease on conservative therapy: prevalence and association
520 with mortality. *Nephrol Dial Transplant.* 2015; 30(10):1718-25.

- 521 14. Morishita S, Tsubaki A, Shirai N. Physical function was related to mortality in patients
522 with chronic kidney disease and dialysis. *Hemodial Int.* 2017; 21(4):483-489.
- 523 15. Chang YT, Wu HL, Guo HR, Cheng YY, Tseng CC, Wang MC, Lin CY, Sung JM. Handgrip
524 strength is an independent predictor of renal outcomes in patients with chronic kidney
525 diseases. *Nephrol Dial Transplant.* 2011; 26(11):3588-95.
- 526 16. Wilkinson TJ, Miksza J, Baker LA, Lightfoot CJ, Watson E, Yates T, et al. Sarcopenia,
527 Chronic Kidney Disease and Risk of Mortality: Findings From 426,839 Individuals in The UK
528 Biobank. *Nephrol Dial Transplant.* 2020; 35(3): gfaa140.MO023.
- 529 17. Vogt BP, Borges MCC, Goés CR, Caramori JCT. Handgrip strength is an independent
530 predictor of all-cause mortality in maintenance dialysis patients. *Clin Nutr.* 2016; 35(6):1429-
531 1433.
- 532 18. Hwang SH, Lee DH, Min J, Jeon JY. Handgrip Strength as a Predictor of All-Cause
533 Mortality in Patients with Chronic Kidney Disease Undergoing Dialysis: A Meta-Analysis of
534 Prospective Cohort Studies. *J Ren Nutr.* 2019; 29(6):471-479.
- 535 19. Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH, et al.
536 Association between physical performance and all-cause mortality in CKD. *J Am Soc Nephrol.*
537 2013; 24(5):822-30.
- 538 20. Konings CJ, Kooman JP, Schonck M, van Kreel B, Heidendal GA, Cheriex EC, et al.
539 Influence of fluid status on techniques used to assess body composition in peritoneal dialysis
540 patients. *Perit Dial Int.* 2003; 23(2):184-90.

- 541 21. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero JJ, Chan W, et al. KDOQI
542 Clinical Practice Guideline for Nutrition in CKD: 2020 Update. *Am J Kidney Dis.* 2020; 76(3):S1-
543 S107.
- 544 22. Kistler BM, Moore LW, Benner D, Biruete A, Boaz M, Brunori G, et al. The International
545 Society of Renal Nutrition and Metabolism Commentary on the National Kidney Foundation
546 and Academy of Nutrition and Dietetics KDOQI Clinical Practice Guideline for Nutrition in
547 Chronic Kidney Disease. *J Ren Nutr.* 2020; S1051-2276(20)30134-5
- 548 23. Silva LF, Matos CM, Lopes GB, Martins MT, Martins MS, Arias LU, Pisoni RL, Lopes AA.
549 Handgrip strength as a simple indicator of possible malnutrition and inflammation in men and
550 women on maintenance hemodialysis. *J Ren Nutr.* 2011; 21(3):235-45.
- 551 24. Amparo FC, Cordeiro AC, Carrero JJ, Cuppari L, Lindholm B, Amodeo C, et al.
552 Malnutrition-inflammation score is associated with handgrip strength in nondialysis-
553 dependent chronic kidney disease patients. *J Ren Nutr.* 2013; 23(4):283-7.
- 554 25. Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Bàràny P, Heimbürger O, et al.
555 Comparative associations of muscle mass and muscle strength with mortality in dialysis
556 patients. *Clin J Am Soc Nephrol.* 2014; 9(10):1720-8.
- 557 26. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The
558 PRISMA statement for reporting systematic reviews and meta-analyses of studies that
559 evaluate health care interventions: explanation and elaboration. *PLoS Med.* 2009;
560 6(7):e1000100.

- 561 27. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance
562 for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic
563 Reviews of Interventions. *Cochrane Database Syst Rev.* 2019; 10:ED000142.
- 564 28. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the
565 measurement of grip strength in clinical and epidemiological studies: towards a standardised
566 approach. *Age Ageing.* 2011; 40(4):423-9.
- 567 29. Shiratori AP, Iop Rda R, Borges Júnior NG, Domenech SC, Gevaerd Mda S. Evaluation
568 protocols of hand grip strength in individuals with rheumatoid arthritis: a systematic review.
569 *Rev Bras Reumatol.* 2014; 54(2):140-7.
- 570 30. Kim C, Kim JK, Lee HS, Kim SG, Song YR. Longitudinal changes in body composition are
571 associated with all-cause mortality in patients on peritoneal dialysis. *Clin Nutr.* 2020; S0261-
572 5614(20)30208-9.
- 573 31. Kmentova T, Valerianova A, Kovarova L, Lachmanova J, Hladinova Z, Malik J. Decrease
574 of muscle strength in vascular access hand due to silent ischaemia. *J Vasc Access.* 2018;
575 19(6):573-577.
- 576 32. Kovarova L, Valerianova A, Kmentova T, Lachmanova J, Hladinova Z, Malik J. Low
577 Cerebral Oxygenation Is Associated with Cognitive Impairment in Chronic Hemodialysis
578 Patients. *Nephron.* 2018; 139(2):113-119.
- 579 33. Tian X, Chen Y, Yang ZK, Qu Z, Dong J. Novel Equations for Estimating Lean Body Mass
580 in Patients With Chronic Kidney Disease. *J Ren Nutr.* 2018; 28(3):156-164.

- 581 34. Limirio LS, Santos HO, Dos Reis AS, de Oliveira EP. (Dis) Agreement between the first
582 and the recent European consensus on definition and diagnosis for sarcopenia in kidney
583 transplant patients. *Eur J Clin Nutr.* 2020; 74(7):1104-1108.
- 584 35. Neves DV, Lanchote VL, Moysés Neto M, Cardeal da Costa JA, Vieira CP, Coelho EB.
585 Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of
586 nebivolol enantiomers. *Br J Clin Pharmacol.* 2016; 82(1):83-91.
- 587 36. Hanauer Schaab E, Lanchote VL, Balthazar Nardotto GH, Marques Pereira MP, Dantas
588 M, Paiva CE, et al. Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of
589 Carvedilol Enantiomers in Patients With Chronic Kidney Disease. *J Clin Pharmacol.* 2020;
590 60(1):75-85.
- 591 37. Viramontes Hörner D, Selby NM, Taal MW. The Association of Nutritional Factors and
592 Skin Autofluorescence in Persons Receiving Hemodialysis. *J Ren Nutr.* 2019; 29(2):149-155.
- 593 38. Frih B, Jaafar H, Mkacher W, Ben Salah Z, Hammami M, Frih A. The Effect of
594 Interdialytic Combined Resistance and Aerobic Exercise Training on Health Related Outcomes
595 in Chronic Hemodialysis Patients: The Tunisian Randomized Controlled Study. *Front Physiol.*
596 2017; 8:288.
- 597 39. Kuki A, Tanaka K, Kushiyama A, Tanaka Y, Motonishi S, Sugano Y. Association of gait
598 speed and grip strength with risk of cardiovascular events in patients on haemodialysis: a
599 prospective study. *BMC Nephrol.* 2019; 20(1):196.
- 600 40. Hasheminejad N, Namdari M, Mahmoodi MR, Bahrampour A, Azmandian J.
601 Association of Handgrip Strength With Malnutrition-Inflammation Score as an Assessment of
602 Nutritional Status in Hemodialysis Patients. *Iran J Kidney Dis.* 2016; 10(1):30-5.

- 603 41. Taşoğlu Ö, Bayrakci N, Sezgin Özcan D, Özkayar N, Taşoğlu İ, Özgirgin N. A functional
604 tool demonstrating the physical function decline independent of age in patients with
605 predialysis chronic kidney disease. *Turk J Med Sci.* 2017; 47(1):91-97.
- 606 42. Lai S, Muscaritoli M, Andreozzi P, Sgreccia A, De Leo S, Mazzaferro S, et al. Sarcopenia
607 and cardiovascular risk indices in patients with chronic kidney disease on conservative and
608 replacement therapy. *Nutrition.* 2019; 62:108-114.
- 609 43. Martinez L, Esteve V, Yeste M, Artigas V, Llagostera S. Neuromuscular
610 electrostimulation: a new therapeutic option to improve radio-cephalic arteriovenous fistula
611 maturation in end-stage chronic kidney disease patients. *Int Urol Nephrol.* 2017; 49(9):1645-
612 1652.
- 613 44. Macagnan FE, Baroni BM, Cristofoli ÉZ, Godoy M, Schardong J, Plentz RDM. Acute
614 effect of photobiomodulation therapy on handgrip strength of chronic kidney disease
615 patients during hemodialysis. *Lasers Med Sci.* 2019; 34(4):835-840.
- 616 45. Omichi Y, Srivareerat M, Panorchan K, Greenhall GH, Gupta S, Davenport A.
617 Measurement of Muscle Strength in Haemodialysis Patients by Pinch and Hand Grip Strength
618 and Comparison to Lean Body Mass Measured by Multifrequency Bio-Electrical Impedance.
619 *Ann Nutr Metab.* 2016; 68(4):268-75.
- 620 46. Vanden Wyngaert K, Celie B, Calders P, Eloot S, Holvoet E, Van Biesen W, et al. Markers
621 of protein-energy wasting and physical performance in haemodialysis patients: A cross-
622 sectional study. *PLoS One.* 2020; 15(7):e0236816.

- 623 47. Vanden Wyngaert K, Van Craenenbroeck AH, Eloot S, Calders P, Celie B, Holvoet E, et
624 al. Associations between the measures of physical function, risk of falls and the quality of life
625 in haemodialysis patients: a cross-sectional study. *BMC Nephrol.* 2020; 21(1):7.
- 626 48. Delanaye P, Bataille S, Quinonez K, Buckinx F, Warling X, Krzesinski JM, et al. Myostatin
627 and Insulin-Like Growth Factor 1 Are Biomarkers of Muscle Strength, Muscle Mass, and
628 Mortality in Patients on Hemodialysis. *J Ren Nutr.* 2019; 29(6):511-520.
- 629 49. Ling LL, Chan YM, Mat Daud Z'. Serum potassium and handgrip strength as predictors
630 of sleep quality among hemodialysis patients in Malaysia. *Asia Pac J Clin Nutr.* 2019;
631 28(2):401-410.
- 632 50. Kittiskulnam P, Carrero JJ, Chertow GM, Kaysen GA, Delgado C, Johansen KL.
633 Sarcopenia among patients receiving hemodialysis: weighing the evidence. *J Cachexia*
634 *Sarcopenia Muscle.* 2017; 8(1):57-68.
- 635 51. Kittiskulnam P, Srijarunerueng S, Chulakadabba A, Thokanit NS, Praditpornsilpa K,
636 Tungsanga K, et al. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function
637 in Pre-Dialysis Chronic Kidney Disease Patients. *Am J Nephrol.* 2020; 51(1):24-34.
- 638 52. D'Alessandro C, Piccoli GB, Barsotti M, Tassi S, Giannese D, Morganti R et al.
639 Prevalence and Correlates of Sarcopenia among Elderly CKD Outpatients on Tertiary Care.
640 *Nutrients.* 2018; 10(12):1951.
- 641 53. Rosa CSDC, Nishimoto DY, Souza GDE, Ramirez AP, Carletti CO, Daibem CGL, et al.
642 Effect of continuous progressive resistance training during hemodialysis on body
643 composition, physical function and quality of life in end-stage renal disease patients: a
644 randomized controlled trial. *Clin Rehabil.* 2018; 32(7):899-908.

- 645 54. Vieira PJ, Silva LR, Maldamer VZ, Cipriano G Jr, Chiappa AM, Schuster R, et al. Skeletal
646 muscle metaboreflex in patients with chronic renal failure. *Clin Physiol Funct Imaging*. 2017;
647 37(2):229-234.
- 648 55. Yunita Sari CM; Suhardjono, Nainggolan G, H Marbun MB, Abdullah M. Correlation
649 between central arterial stiffness and handgrip strength in chronic hemodialysis patients.
650 *Saudi J Kidney Dis Transpl*. 2019; 30(4):891-897.
- 651 56. Marini AC, Motobu RD, Freitas ATV, Laviano A, Pimentel GD. Pre-sarcopenia in
652 patients undergoing hemodialysis: Prevalence and association with biochemical parameters.
653 *Clin Nutr ESPEN*. 2018; 28:236-238.
- 654 57. Bogataj Š, Pajek M, Buturović Ponikvar J, Pajek J. Outcome Expectations for Exercise
655 and Decisional Balance Questionnaires Predict Adherence and Efficacy of Exercise Programs
656 in Dialysis Patients. *Int J Environ Res Public Health*. 2020; 17(9):3175.
- 657 58. Silva DM, Queiroz NP, Freitas ATVS, Passarelli M, Corgosinho FC, Peixoto MDRG.
658 Serum advanced glycation end products are not associated with muscle strength in
659 hemodialysis patients. *Eur J Clin Nutr*. 2019; 73(4):617-623.
- 660 59. Viramontes Hörner D, Selby NM, Taal MW. Skin autofluorescence and malnutrition as
661 predictors of mortality in persons receiving dialysis: a prospective cohort study. *J Hum Nutr*
662 *Diet*. 2020; 33(6):852-861.
- 663 60. Bučar Pajek M, Čuk I, Pajek J. Vascular Access Effects on Motor Performance and
664 Anthropometric Indices of Upper Extremities. *Ther Apher Dial*. 2016; 20(3):295-301.

- 665 61. Bučar Pajek M, Leskošek B, Vivoda T, Svilan K, Čuk I, Pajek J. Integrative Examination
666 of Motor Abilities in Dialysis Patients and Selection of Tests for a Standardized Physical
667 Function Assessment. *Ther Apher Dial.* 2016; 20(3):286-94.
- 668 62. Bučar Pajek M, Pajek J. Characterization of deficits across the spectrum of motor
669 abilities in dialysis patients and the impact of sarcopenic overweight and obesity. *Clin Nutr.*
670 2018; 37(3):870-877.
- 671 63. Fess E. Clinical assessment recommendations. Chicago: American Society of Hand
672 Therapists; 1992.
- 673 64. Mathiowetz V. Comparison of Rolyan and Jamar dynamometers for measuring grip
674 strength. *Occup Ther Int.* 2002; 9(3):201-9.
- 675 65. Amaral JF, Mancini M, Novo Júnior JM. Comparison of three hand dynamometers in
676 relation to the accuracy and precision of the measurements. *Rev Bras Fisioter.* 2012;
677 16(3):216-24.
- 678 66. Proud D, Rezaie M, Lau D, Ketchell RI, Duckers J. 344 Which grip device to grip? A
679 comparison of hand grip strength dynamometers in adult patients with cystic fibrosis. *J Cyst*
680 *Fibros.* 2017; 1;16:S151.
- 681 67. El-Katab S, Omichi Y, Srivareerat M, Davenport A. Pinch grip strength as an alternative
682 assessment to hand grip strength for assessing muscle strength in patients with chronic
683 kidney disease treated by haemodialysis: a prospective audit. *J Hum Nutr Diet.* 2016; 29(1):48-
684 51.
- 685 68. Hogrel JY. Grip strength measured by high precision dynamometry in healthy subjects
686 from 5 to 80 years. *BMC Musculoskelet Disord.* 2015; 16:139.

- 687 69. El-Sais WM, Mohammad WS. Influence of different testing postures on hand grip
688 strength. *Eur Sci J*. 2014; 10(36).
- 689 70. Watanabe T, Owashi K, Kanauchi Y, Mura N, Takahara M, Ogino T. The short-term
690 reliability of grip strength measurement and the effects of posture and grip span. *J Hand Surg*
691 *Am*. 2005; 30(3):603-9.
- 692 71. Balogun JA, Akinloye AA, Adenlola SA. Grip strength as a function of age, height, body
693 weight and Quetelet index. *Physio Ther Prac*. 1991; 7(2):111-9.
- 694 72. Jiang K, Slee A, Davenport A. Body composition and weakness of hand grip strength
695 and pinch strength in patients with chronic kidney disease from different ethnic backgrounds.
696 *J Hum Nutr Diet*. 2020. Epub ahead of print.
- 697 73. Trampisch US, Franke J, Jedamzik N, Hinrichs T, Platen P. Optimal Jamar dynamometer
698 handle position to assess maximal isometric hand grip strength in epidemiological studies. *J*
699 *Hand Surg Am*. 2012; 37(11):2368-73.
- 700 74. Fess E, Moran C. Clinical assessment recommendations. 1st ed. Indianapolis: American
701 Society of Hand Therapists; 1981.
- 702 75. Sousa-Santos AR, Amaral TF. Differences in handgrip strength protocols to identify
703 sarcopenia and frailty - a systematic review. *BMC Geriatr*. 2017; 17(1):238.
- 704 76. Jansen CW, Patterson R, Viegas SF. Effects of fingernail length on finger and hand
705 performance. *J Hand Ther*. 2000; 13(3):211-7.
- 706 77. Mathiowetz V, Rennells C, Donahoe L. Effect of elbow position on grip and key pinch
707 strength. *J Hand Surg Am*. 1985; 10(5):694-7.

- 708 78. De S, Sengupta P, Maity P, Pal A, Dhara PC. Effect of body posture on hand grip
709 strength in adult Bengalee population. *J Ex Sci Physio*. 2011; 7(2):79-88.
- 710 79. Balogun JA, Akomolafe CT, Amusa LO. Grip strength: effects of testing posture and
711 elbow position. *Arch Phys Med Rehabil*. 1991; 72(5):280-3.
- 712 80. Su CY, Lin JH, Chien TH, Cheng KF, Sung YT. Grip strength in different positions of elbow
713 and shoulder. *Arch Phys Med Rehabil*. 1994; 75(7):812-5.
- 714 81. Parvatikar VB, Mukkannavar PB. Comparative study of grip strength in different
715 positions of shoulder and elbow with wrist in neutral and extension positions. *J Ex Sci Physio*.
716 2009; 5(2):67.
- 717 82. Wu KT, Chou WY, Ko JY, Siu KK, Yang YJ. Inferior outcome of rotator cuff repair in
718 chronic hemodialytic patients. *BMC Musculoskelet Disord*. 2019; 20(1):209.
- 719 83. O'Driscoll SW, Horii E, Ness R, Cahalan TD, Richards RR, An KN. The relationship
720 between wrist position, grasp size, and grip strength. *J Hand Surg Am*. 1992; 17(1):169-77.
- 721 84. Leal VO, Mafra D, Fouque D, Anjos LA. Use of handgrip strength in the assessment of
722 the muscle function of chronic kidney disease patients on dialysis: a systematic review.
723 *Nephrol Dial Transplant*. 2011; 26(4):1354-60.
- 724 85. Delanaye P, Quinonez K, Buckinx F, Krzesinski JM, Bruyère O. Hand grip strength
725 measurement in haemodialysis patients: before or after the session? *Clin Kidney J*. 2018;
726 11(4):555-558.
- 727 86. Carrero JJ, Chmielewski M, Axelsson J, Snaedal S, Heimbürger O, Bárány P, et al.
728 Muscle atrophy, inflammation and clinical outcome in incident and prevalent dialysis patients.
729 *Clin Nutr*. 2008; 27(4):557-64.

- 730 87. Walsh OT, CHT L. Effect of Verbal Directions on Grip Strength Evaluated Using the
731 Handheld Dynamometer. *Department of Occupational Therapy Faculty Papers*. Paper 66.
732 Available at: <https://jdc.jefferson.edu/otfp/66>
- 733 88. Kamimura T, Ikuta Y. Evaluation of grip strength with a sustained maximal isometric
734 contraction for 6 and 10 seconds. *J Rehabil Med*. 2001; 33(5):225-9.
- 735 89. Abizanda P, Navarro JL, García-Tomás MI, López-Jiménez E, Martínez-Sánchez E,
736 Paterna G. Validity and usefulness of hand-held dynamometry for measuring muscle strength
737 in community-dwelling older persons. *Arch Gerontol Geriatr*. 2012; 54(1):21-7.
- 738 90. Coldham F, Lewis J, Lee H. The reliability of one vs. three grip trials in symptomatic and
739 asymptomatic subjects. *J Hand Ther*. 2006; 19(3):318-26.
- 740 91. Hall RK, Rutledge J, Luciano A, Hall K, Pieper CF, Colón-Emeric C. Physical Function
741 Assessment in Older Hemodialysis Patients. *Kidney Med*. 2020; 2(4):425-431.
- 742 92. Painter P, Marcus R. Physical function and gait speed in patients with chronic kidney
743 disease. *Nephrol Nurs J*. 2013; 40(6):529-38,
- 744 93. Bennett PN, Fraser S, Barnard R, Haines T, Ockerby C, Street M, et al. Effects of an
745 intradialytic resistance training programme on physical function: a prospective stepped-
746 wedge randomized controlled trial. *Nephrol Dial Transplant*. 2016; 31(8):1302-9.
- 747 94. Cooper C. *Fundamentals of Hand Therapy-E-Book: Clinical Reasoning and Treatment*
748 *Guidelines for Common Diagnoses of the Upper Extremity*. 2014: Elsevier Health Sciences.
- 749 95. Tanaka S, Sugiura T, Yamashita S, Dohi Y, Kimura G, Ohte N. Differential response of
750 central blood pressure to isometric and isotonic exercises. *Sci Rep*. 2014; 4:5439.

751 96. Chrysant SG. Current evidence on the hemodynamic and blood pressure effects of
752 isometric exercise in normotensive and hypertensive persons. *J Clin Hypertens (Greenwich)*.
753 2010; 12(9):721-6.


754 97. Jung MC, Hallbeck MS. Quantification of the effects of instruction type, verbal
755 encouragement, and visual feedback on static and peak handgrip strength. *Int J Ind Ergo*.
756 2004; 34(5): 367-374.

757 98. Bohannon RW. Minimal clinically important difference for grip strength: a systematic
758 review. *J Phys Ther Sci*. 2019; 31(1):75-78.

759

760 Figure 1. PRISMA diagram

761



762

763

764
765

Table 1. Recommended protocol for measuring handgrip strength in people with CKD

1. Participants should be seated in a straight-backed chair with the feet flat on the floor. Use the same chair for every measurement if possible. If the patient cannot be seated, assessment whilst standing is suitable.
2. The shoulders should be adducted (0°) and neutrally rotated with the elbow flexed at 90° .
3. The forearm should be placed in a neutral rotation, and the wrist between 0° and 30° extension and between 0° and 15° ulnar deviation.
4. The arm should *not be supported* by the patient, examiner, or by an armrest.
5. The dynamometer should be presented vertically and in line with the forearm to maintain the standard forearm and wrist positions.



Figure 2A. Seating positron with shoulders adducted, elbow flexed at 90° , and forearm in neural position

6. Position the hand so that the thumb is around one side of the handle and the four fingers are around the other side. The instrument should feel comfortable in the hand.

7. Alter the position of the handle if necessary - on a Jamar® instrument, the second-hand position should be used. Rarely, a small-handed person or a large-handed person may require the handle to be at the first or third position setting.



Figure 2B. Dynamometer presented vertically in line with forearm. Hand is positioned with the thumb is around one side of the handle and the four fingers are around the other side.

8. In patients who have a fistula, use the *non-fistula* arm.
9. In regard to the dialysis session, assessing HGS *before* the dialysis session (and before connection to the machine) is preferable.
10. To limit the variability in physiologic status and dialysis fatigue, HGS should be assessed before the participant's *mid-week dialysis session*.
11. Encourage the participant to squeeze as long and as tightly as possible using a set of standardised instructions: '*I want you to hold the handle like this and squeeze as hard as you can*'. The examiner then demonstrates and then gives the dynamometer to the patient. After the patient is positioned appropriately, the examiner says, '*Are you*

ready? Squeeze as hard as you can'. As the patient begins to squeeze, the examiner says, 'Harder!... Harder!... Relax'.

12. Grip force should be applied smoothly, without rapid wrenching or jerking motion.
13. No visual or auditory feedback should be provided; thus, the dynamometer's dial should be turned away from patients so they cannot see the display.
14. The contraction time should be *at least* 3 seconds, and no more than 6 seconds. The patient should exhale during the grip.
15. Read grip strength in kilograms (kg) from the outside dial and record the result to the nearest 1 kg on the data entry form.
16. For some devices, the minimal reading is 5 kg (check instrument instructions). If an individual cannot reach the minimal value, record this to the devices minimal detectable score.
17. Rest for at least 1 minute (between hands) and repeat measurement on the other hand *if appropriate*.
18. Do two further measurements (for each hand alternating sides *if appropriate, i.e., no fistula access*) to give *three readings* in total for each side.
19. If limited on time, one measurement from the dominant hand (or non-fistula arm) is sufficient.
20. The *highest value* should be used in statistical analyses.
21. Record hand dominance in all patients, even if both hands were not used, i.e., right, left or ambidextrous (people who can genuinely write with both hands).
22. The minimal important difference in a dialysis patient is estimated to be 3.4 kg, whilst a clinical important difference is estimated to be 5-6.5 kg [98].
23. Deviations in the procedure are strongly discouraged; however, when it is impossible to fully implement this protocol, namely due to the individuals' health conditions, any variation should be reported.

768 **Table 2. Checklist for handgrip strength reporting**

769

- | |
|--|
| <ul style="list-style-type: none"><input type="checkbox"/> Dynamometer characteristics (brand, model, resolution, calibration, and handle position)<input type="checkbox"/> Posture (standing or sitting)<input type="checkbox"/> Arm position (including shoulder, elbow, and wrist positions)<input type="checkbox"/> Inclusion of access arm (if appropriate)<input type="checkbox"/> Number of trials performed<input type="checkbox"/> How the score was derived<input type="checkbox"/> Acquisition (time taken to record HGS) and rest time between intervals<input type="checkbox"/> The applied instructions<input type="checkbox"/> Any cut-off points to identify low hand grip strength<input type="checkbox"/> Time of day tested (including in relation to dialysis if appropriate) |
|--|

770